Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1501 - 1550 of 1864 results
- Phase Ib Trial Assessing Autologous, Tumor-pulsed Dendritic Cells as a Vaccine Administered With or Without IL-2 in Patients With Metastatic Melanoma.
- Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax): A Phase 2 Trial.
- Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer.
- rVSV(MDelta51)-M3 Is an Effective and Safe Oncolytic Virus for Cancer Therapy.
- Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck.
- Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma.
- Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy.
- JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase.
- Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
- Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo.
- HSV-1 amplicon viral vector-mediated gene transfer to human bone marrow-derived mesenchymal stem cells.
- Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10: Applications for Cancer Gene Therapy.
- Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy.
- Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
- Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [(18)F]-labeled 2'-deoxycytidine analog.
- Chemokine Receptor CCR7 Expression Correlates with Lymph Node Metastasis in Pancreatic Cancer.
- Oncolytic HSV-1 Infection of Tumors Induces Angiogenesis and Upregulates CYR61.
- Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
- Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.
- A DNA adjuvant encoding a fusion protein between anti-CD3 single-chain Fv and AIMP1 enhances T helper type 1 cell-mediated immune responses in antigen-sensitized mice.
- Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.
- A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.
- Mode-of-Action, Efficacy, and Safety of a Homologous Multi-Epitope Vaccine in a Murine Model for Adjuvant Treatment of Renal Cell Carcinoma.
- Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
- PILAR is a novel modulator of human T cell expansion.
- Isolation and Functional Characterization of Single Domain Antibody Modulators of Caspase-3 and Apoptosis.
- Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-alpha, and tegafur-uracil: a single-institution experience.
- Small neutralizing molecules to inhibit actions of the chemokine CXCL12.
- A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
- Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
- Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes.
- Directed evolution generates a novel oncolytic virus for the treatment of colon cancer.
- Novel Bimodal Bifunctional Ligands for Radioimmunotherapy and Targeted MRI.
- In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of anti-tumor activity.
- Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines.
- Targeting IL-13R{alpha}2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
- A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers.
- DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis.
- Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis.
- Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo.
- In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF-{beta}1.
- Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant.
- Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells.
- European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas.
- Preparation of anti-sperm protein 17 immunomagnetic nanoparticles for targeting cell.
- Basic fibroblast growth factor loaded biodegradable PCL-PEG-PCL copolymeric nanoparticles: preparation, in vitro release and immunogenicity study.
- CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
- Adoptive immunotherapy for pancreatic cancer: Cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
- Establishment of combined immuno-chemotherapy with systemically administered gemcitabine and intra-portal administration of interleukin-2 in murine models of liver metastases of pancreatic cancer.
- Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein.